Inhibitors of topoisomerase II enzymes: A unique group of environmental mutagens and carcinogens

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 400, Issue 1-2, 1998, Pages 271-278

  Ferguson, Lynnette R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

DNA adduct; Environmental mutagen; Human carcinogen; Illegitimate recombination; Topoisomerase inhibitor

Indexed keywords

AMSACRINE; CARCINOGEN; DOXORUBICIN; ETOPOSIDE; GYRASE INHIBITOR; MERBARONE;

ANEUPLOIDY; ARTICLE; CHEMICAL MUTAGENESIS; CHROMOSOME DELETION; DNA ALKYLATION; ENZYME INHIBITION; GENE MUTATION; GENETIC RECOMBINATION; HUMAN; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CARCINOGENICITY TESTS; CARCINOGENS, ENVIRONMENTAL; DNA; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; HUMANS; MUTAGENS;

EID: 0032565511     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(98)00039-6     Document Type: Article

References (43)

1. [1] C. Sandoval, C.H. Pui, L.C. Bowman, D. Heaton, C.A. Hurwitz, S.C. Raimondi, F.G. Behm, D.R. Head, Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase-II inhibitors, and irradiation, J. Clin. Oncol. 11 (1993) 1039-1045.
2. [2] R.K. Ralph, W. Judd, Y. Pommier, K.W. Kohn, DNA topoisomerases, in: S. Neidle, M. Waring (Eds.), Topics in Molecular and Structural Biology: Molecular Aspects of Anticancer Drug-DNA Interactions, 1st edn., Vol. 2, Macmillan, Kent, 1994, pp. 1-95.
3. [3] J. Roca, R. Ishida, J.M. Berger, T. Andoh, J.C. Wang, Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp, Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 1781-1785.
4. [4] A. Felix, B.J. Lange, M.R. Hosler, J. Fertala, M.A. Bjornsti, Chromosome band 11Q23 translocation breakpoints are DNA topoisomerase II cleavage sites, Cancer Res. 55 (1995) 4287-4292.
5. [5] J.A. Ross, J.D. Potter, L.L. Robison, Infant leukemia, topoisomerase inhibitors and the MLL gene, J. Natl. Cancer Inst. 86 (1994) 1678-1680.
6. [6] L.R. Ferguson, A. Pearson, Chromosomal changes in Chinese hamster AA8 cells caused by podophyllin, a common treatment for genital warts, Mutation Res. 266 (1992) 231-239.
7. [7] C.A. Austin, S. Patel, K. Ono, H. Nakane, L.M. Fisher, Site-specific DNA cleavage by mammalian DNA topoisomerase-II induced by novel flavone and catechin derivatives, Biochem. J. 282 (1992) 883-889.
8. [8] Y. Kashiwada, G. Nonaka, I. Nishioka, K.J. Lee, I. Bori, Y. Fukushima, K.F. Bastow, K.H. Lee, Tannins as potent inhibitors of DNA topoisomerase II in vitro, J. Pharm. Sci. 82 (1993) 487-492.
9. [9] H. Chen, D.A. Eastmond, Topoisomerase inhibition by phenolic metabolites: a potential mechanism for benzene's clastogenic effects, Carcinogenesis 16 (1995) 2301-2307.
10. [10] G.M. Williams, Classification of genotoxic and epigenetic hepatocarcinogens using liver culture assays, Ann. New York Acad. Sci. 349 (1980) 273-282.
11. [11] B.E. Butterworth, T.J. Slaga, Nongenotoxic mechanisms in carcinogenesis, Banbury Report, Vol. 25, Cold Spring Harbor Laboratory Press, NY, 1987.
12. [12] J.A. Ashby, D. Paton, The influence of chemical structure on the extent and sites of carcinogenesis for 522 rodent carcinogens and 55 different human carcinogen exposures, Mutation Res. 286 (1993) 3-74.
13. [13] L.R. Ferguson, B.C. Baguley, Topoisomerase II enzymes and mutagenicity, Environ. Mol. Mutagen. 24 (1994) 245-267.
14. [14] L.A. Zwelling, M.R. Mattern, DNA-repair deficiencies do not affect intercalator-induced cytotoxicity or DNA scission in human cells, Mutation Res. 104 (1982) 295-304.
15. [15] W.W. Au, M.A. Butler, T.S. Matney, T.L. Loo, Comparative structure-genotoxicity study of three aminoanthraquinone drugs and doxorubicin, Cancer Res. 41 (1981) 376-379.
16. [16] L.R. Ferguson, P. van Zijl, B.C. Baguley, Mutagenicity profiles of newer amsacrine analogues with activity against solid tumours; comparison of microbial and mammalian systems, Eur. J. Cancer Clin. Oncol. 25 (1989) 255-261.
17. [17] W.R. Wilson, N.M. Harris, L.R. Ferguson, Comparison of the mutagenic and clastogenic activity of amsacrine and other DNA-intercalating drugs in cultured V79 Chinese hamster cells, Cancer Res. 44 (1984) 4420-4431.
18. [18] L.R. Ferguson, P.M. Turner, D.W. Hart, K.R. Tindall, Amsacrine-induced mutations in AS52 cells, Environ. Mol. Mutagen., in press.
19. [19] R.H. Zhou, P. Wang, Y. Zou, C.K. Jacksoncook, L.F. Povirk, A precise interchromosomal reciprocal exchange between hot spots for cleavable complex formation by topoisomerase II in amsacrine-treated Chinese hamster ovary cells, Cancer Res. 57 (1997) 4699-4702.
20. [20] L.R. Ferguson, G. Whiteside, K.M. Holdaway, B.C. Baguley, Application of fluorescence in situ hybridisation to studying the relationship between cytotoxicity, chromosomal aberrations and changes in chromosome number after treatment with the topoisomerase II inhibitor, amsacrine, Environ. Mol. Mutagen. 27 (1996) 255-262.
21. [21] C. Holm, T. Stearns, D. Botstein, DNA topoisomerase II must act at mitosis to prevent nondisjunction and chromosome breakage, Mol. Cell. Biol. 9 (1989) 159-168.
22. [22] D. Rose, W. Thomas, C. Holm, Segregation of recombined chromosomes in meiosis I requires DNA topoisomerase II, Cell 60 (1990) 1009-1017.
23. [23] P.B. Moens, W.C. Earnshaw, Anti-topoisomerase II recognises meiotic chromosome cores, Chromosoma 98 (1989) 317-322.
24. [24] L.R. Ferguson, J.A. Allen, J.M. Mason, Meiotic recombination and germ cell aneuploidy, Environ. Mol. Mutagen. 28 (1996) 192-210.
25. [25] G.N. Giroux, Chromosomal synapsis and meiotic recombination, in: R. Kucherlapati, G.R. Smith (Eds.), Genetic Recombination, American Society for Microbiology, WA, 1988, pp. 465-496.
26. [26] J.B. Bishop, K.L. Witt, In vivo germ cell mutagenesis assays, in: D.H. Philips, S. Venitt (Eds.), Environmental Mutagenesis, Bios Scientific Publishers, Oxford, UK, 1996, pp. 155-179.
27. [27] M. Kallio, J. Lahdetie, Fragmentation of centromeric DNA and prevention of homologous chromosome segregation in male mouse meiosis in vivo by the topoisomerase II inhibitor etoposide, Mutagenesis 11 (1996) 435-443.
28. [28] J. Lahtedie, A. Keiski, A. Suutari, J. Toppari, Etoposide (VP-16) is a potent inducer of micronuclei in male rat meiosis: spermatid micronucleus test and DNA flow cytometry after etoposide treatment, Environ. Mol. Mutagen. 24 (1994) 192-202.
29. [29] M. Kallio, J. Lahdetie, Effects of the DNA topoisomerase II inhibitor merbarone in male mouse meiotic divisions in vivo: cell cycle arrest and induction of aneuploidy, Environ. Mol. Mutagen. 29 (1997) 16-27.
30. [30] M.A. Katoh, K.T. Cain, L.A. Hughes, L.B. Foxworth, J.B. Bishop, W.M. Generoso, Female-specific dominant lethal effects in mice, Mutation Res. 230 (1990) 205-217.
31. [31] J.B. Bishop, L.A. Hughes, L.R. Ferguson, W.M. Generoso, Amsacrine: a topoisomerase inhibitor which is a female specific germ cell mutagen, Environ. Mol. Mutagen. 27 (S27) (1996) 8.
32. [32] C.S. Downes, R.T. Johnson, DNA topoisomerases and DNA repair, Bioessays 8 (1988) 179-184.
33. [33] L.R. Ferguson, B.C. Baguley, Multiple drug resistance and mutagenicity, Mutation Res. 285 (1993) 79-90.
34. [34] S. De Flora, A. Camoirano, C. Cartiglia, L.R. Ferguson, Modulation of the potency of promutagens and direct acting mutagens in bacteria by inhibitors of the multidrug resistance mechanism, Mutagenesis 12 (1997) 431-436.
35. [35] S.M. Morris, O.E. Domon, L.J. McGarrity, J.J. Chen, D.A. Casciano, Programmed cell death and mutation induction in AHH-1 human lymphoblastoid cells exposed to m-AMSA, Mutation Res. 329 (1995) 79-96.
36. [36] C. Demarcq, R.T. Bunch, D. Creswell, A. Eastman, The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells, Cell Growth Differ. 5 (1994) 983-993.
37. [37] S.W. Lowe, H.E. Ruley, T. Jacks, D.E. Housman, p53-dependent apoptosis modulates the cytotoxicity of anticancer agents, Cell 74 (1993) 957-967.
38. [38] A. Skandalis, B.W. Glickman, Endogenous gene systems for the study of mutational specificity in mammalian cells, Cancer Cells (Cold Spring Harbor) 2 (1990) 79-83.
39. [39] C.C. Harris, Chemical and physical carcinogenesis: advances and perspectives for the 1990s, Cancer Res. 51 (1995) 5023s-5044s, (Suppl.).
40. [40] P. Hainaut, T. Soussi, B. Shomer, M. Hollstein, M. Greenblatt, E. Hovig, C.C. Harris, R. Montesano, Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects, Nucleic Acids Res. 25 (1997) 151-157.
41. [41] D.E.G. Shuker, D.J. Benford, DNA modification in carcinogen risk assessment in relation to diet: recent advances and some perspectives, Biomarkers 2 (1997) 265-278.
42. [42] F.A. De la Inglesia, J.E. Fitzgerald, E.J. McGuire, S.-N. Kim, C.L. Heifitz, G.D. Stoner, Bacterial and mammalian cell mutagenesis, sister-chromatid exchange and mouse lung adenoma bioassay with the antineoplastic acridine derivative, J. Toxicol. Environ. Health 14 (1984) 667-681.
43. [43] M.J. Graziano, C.L. Courtney, F.F. Meierhenry, T. Kheoh, D.G. Pegg, A.W. Gough, Carcinogenicity of the anticancer topoisomerase inhibitor, amsacrine, in Wistar rats, Fundam. Appl. Toxicol. 32 (1996) 53-65.